A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400 mg Or 1000 mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy

Trial Profile

A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400 mg Or 1000 mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Tideglusib (Primary)
  • Indications Myotonic dystrophy
  • Focus Adverse reactions
  • Sponsors AMO Pharma
  • Most Recent Events

    • 25 Sep 2017 According to an AMO Pharma media release, data from the study will be presented at the American Neurological Association's (ANA) 2017 Annual Meeting.
    • 25 Sep 2017 Interim results for the first cohort published in an AMO Pharma media release.
    • 02 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top